^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RG6540

    i
    Other names: RG6540, RG-6540, RG 6540, P-CD19CD20-ALLO1, PCD19CD20ALLO1, P CD19CD20 ALLO1
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    3ms
    A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis (clinicaltrials.gov)
    P1, N=60, Recruiting, Genentech, Inc. | Not yet recruiting --> Recruiting | Trial completion date: Feb 2032 --> Aug 2032 | Trial primary completion date: Feb 2032 --> Aug 2032
    Enrollment open • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • RG6540
    6ms
    A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Genentech, Inc.
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • RG6540
    7ms
    A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov)
    P1, N=162, Not yet recruiting, Genentech, Inc.
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • RG6540 • rimiducid (AP1903)
    over1year
    P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies (clinicaltrials.gov)
    P1, N=100, Recruiting, Poseida Therapeutics, Inc. | Initiation date: Jan 2024 --> Apr 2024
    Trial initiation date • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CD20 positive
    |
    RG6540 • rimiducid (AP1903)
    almost2years
    P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies (clinicaltrials.gov)
    P1, N=100, Recruiting, Poseida Therapeutics, Inc. | Not yet recruiting --> Recruiting | N=70 --> 100
    Enrollment open • Enrollment change • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CD20 positive
    |
    RG6540 • rimiducid (AP1903)
    over2years
    P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies (clinicaltrials.gov)
    P1, N=70, Not yet recruiting, Poseida Therapeutics, Inc.
    New P1 trial • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CD20 positive
    |
    RG6540 • rimiducid (AP1903)